Ticagrelor versus Prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry

Minerva Cardiol Angiol

21 Giugno Giu 2021 one month ago
  • Gili S

The use of potent P2Y12 inhibitors (ticagrelor & prasugrel) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary interventions (PCI) is a class I recommendation. We performed a sex-specific analysis comparing the difference in efficacy and safety outcomes between ticagrelor and prasugrel in a real-world ACS population.

Reference

Ticagrelor versus Prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. Al Raisi S, Protty M, Raposeiras-Roubín S, D'Ascenzo F, Abu-Assi E, Ariza-Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Quadri G, Rognoni A, Boccuzzi G, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Flores-Blanco P, Varbella F, Cespón-Fernández M, Gallo D, Morbiducci U, Dominguez-Rodriguez A, Cequier A, Gaita F, Alexopoulos D, Valgimigli M, Íñiguez-Romo A, Kinnaird T. Minerva Cardiol Angiol. 2021 Jun 17. doi: 10.23736/S2724-5683.21.05591-5

Go to PubMed